Safety and persistence of WT1-specific T-cell receptor gene2transduced lymphocytes in patients with AML and MDS

Isao Tawara, Shinichi Kageyama, Yoshihiro Miyahara, Hiroshi Fujiwara, Tetsuya Nishida, Yoshiki Akatsuka, Hiroaki Ikeda, Kazushi Tanimoto, Seitaro Terakura, Makoto Murata, Yoko Inaguma, Masahiro Masuya, Naoki Inoue, Tomohide Kidokoro, Sachiko Okamoto, Daisuke Tomura, Hideto Chono, Ikuei Nukaya, Junichi Mineno, Tomoki NaoeNobuhiko Emi, Masaki Yasukawa, Naoyuki Katayama, Hiroshi Shiku

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Wilms’ tumor 1 (WT1) is constantly expressed in leukemic cells of acute leukemia and myelodysplastic syndrome (MDS). A T-cell receptor (TCR) that specifically reacts with WT1 peptide in the context of HLA-A*24:02 has been identified. We conducted a first-inhuman trial of TCR–gene transduced T-cell (TCR–T-cell) transfer in patients with refractory acute myeloblastic leukemia (AML) and high-risk MDS to investigate the safety and cell kinetics of the T cells. The WT1-specific TCR-gene was transduced to T cells using a retroviral vector encoding small interfering RNAs for endogenous TCR genes. The T cells were transferred twice with a 4-week interval in a dose-escalating design. After the second transfer, sequential WT1 peptide vaccines were given. Eight patients, divided into 2 dose cohorts, received cell transfer. No adverse events of normal tissue were seen. The TCR-T cells were detected in peripheral blood for 8 weeks at levels proportional to the dose administered, and in 5 patients, they persisted throughout the study period. The persisting cells maintained ex vivo peptide-specific immune reactivity. Two patients showed transient decreases in blast counts in bone marrow, which was associated with recovery of hematopoiesis. Four of 5 patients who had persistent T cells at the end of the study survived more than 12 months. These results suggest WT1-specific TCR-T cells manipulated by ex vivo culture of polyclonal peripheral lymphocytes survived in vivo and retained the capacity to mount an immune reaction to WT1. This trial was registered at www.umin.ac.jp as #UMIN000011519.

Original languageEnglish
Pages (from-to)1985-1994
Number of pages10
JournalBlood
Volume130
Issue number18
DOIs
Publication statusPublished - 02-11-2017

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Tawara, I., Kageyama, S., Miyahara, Y., Fujiwara, H., Nishida, T., Akatsuka, Y., Ikeda, H., Tanimoto, K., Terakura, S., Murata, M., Inaguma, Y., Masuya, M., Inoue, N., Kidokoro, T., Okamoto, S., Tomura, D., Chono, H., Nukaya, I., Mineno, J., ... Shiku, H. (2017). Safety and persistence of WT1-specific T-cell receptor gene2transduced lymphocytes in patients with AML and MDS. Blood, 130(18), 1985-1994. https://doi.org/10.1182/blood-2017-06-791202